Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone Journal of Clinical Oncology, 03/15/2012
Kang JH et al. – The authors found no median overall survival (OS) difference between docetaxel and irinotecan. This is the largest phase III trial comparing salvage chemotherapy (SLC) plus best supportive care (BSC) with BSC alone in advanced gastric cancer (AGC). In pretreated patients, SLC is tolerated and significantly improves OS when added to BSC.